The 2022 Tandem Meetings | Real-world long-term outcomes of patients with LBCL treated with axi-cel
Saurabh Dahiya, MD, University of Maryland School of Medicine, Baltimore, MD, presents data from a study evaluating the real-world long-term outcomes of patients with large B-cell lymphoma (LBCL) treated with standard of care (SOC) axicabtagene ciloleucel (axi-cel). After a median follow-up of 32 months, the study reported an overall survival (OS) and progression-free survival (PFS) at three years of 52% and 47% respectively, which is comparable to the results shown in the registrational ZUMA-1 study (NCT02348216). This study also found that a significant number of patients developed prolonged cytopenia (10%) and secondary malignant neoplasms (7%) after CAR-T therapy. Further investigation is required to better understand these long-term side effects. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
